Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania.

The Journal of Infectious Diseases
Zacchaeus AnywaineDeborah Watson-Jones

Abstract

Ebola vaccine development was accelerated in response to the 2014 Ebola virus infection outbreak. This phase 1 study (VAC52150EBL1004) assessed safety, tolerability, and immunogenicity of heterologous 2-dose Ad26.ZEBOV, MVA-BN-Filo vaccination regimens in the Lake Victoria Basin of Tanzania and Uganda in mid-level altitude, malaria-endemic settings. Healthy volunteers aged 18-50 years from Tanzania (n = 25) and Uganda (n = 47) were randomized to receive placebo or active vaccination with Ad26.ZEBOV or MVA-BN-Filo (first vaccination), followed by MVA-BN-Filo or Ad26.ZEBOV (second vaccination) dose 2, respectively, with intervals of 28 or 56 days. Seventy-two adults were randomized to receive vaccine (n = 60) or placebo (n = 12). No vaccine-related serious adverse events were reported. The most frequent solicited local and systemic adverse events were injection site pain (frequency, 70%, 66%, and 42% per dose for MVA-BN-Filo, Ad26.ZEBOV, and placebo, respectively) and headache (57%, 56%, and 46%, respectively). Adverse event patterns were similar among regimens. Twenty-one days after dose 2, 100% of volunteers demonstrated binding antibody responses against Ebola virus glycoprotein, and 87%-100% demonstrated neutralizing antibody...Continue Reading

References

Mar 20, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·John NeffUNKNOWN Armed Forces Epidemiological Board
May 24, 2011·Malaria Journal·Sandra A MudhuneRobert W Snow
Dec 29, 2011·The Journal of Clinical Investigation·Nicole FrahmM Juliana McElrath
Apr 2, 2015·The New England Journal of Medicine·Jason A RegulesUNKNOWN rVSVΔG-ZEBOV-GP Study Group
Apr 20, 2016·JAMA : the Journal of the American Medical Association·Iain D MilliganMatthew D Snape
Oct 14, 2016·Nature·Edward C HolmesKristian G Andersen
Mar 16, 2017·JAMA : the Journal of the American Medical Association·Rebecca L WinslowMatthew D Snape
Aug 2, 2017·Vaccine· World Health Organization
Oct 12, 2017·The New England Journal of Medicine·Stephen B KennedyUNKNOWN PREVAIL I Study Group

❮ Previous
Next ❯

Citations

Nov 30, 2019·Expert Review of Vaccines·Keesha M MatzHeinz Feldmann
Dec 11, 2019·The Journal of Infectious Diseases·Helen R WagstaffeMartin R Goodier
Jun 21, 2019·Science Translational Medicine·Rino RappuoliDavid E Bloom
Oct 12, 2019·The Journal of Infectious Diseases·Daniel G Bausch, Peter Piot
Jul 15, 2020·Angewandte Chemie·Tingting YeBruno G De Geest
Sep 8, 2020·Paediatrics and International Child Health·Devika DixitMichael T Hawkes
Apr 22, 2020·The Journal of Clinical Investigation·Helen R WagstaffeMartin R Goodier
Jun 25, 2020·Disaster Medicine and Public Health Preparedness·Charles BeadlingFrederick Burkle
Sep 6, 2020·Nature Reviews. Immunology·Mangalakumari JeyanathanZhou Xing
Oct 8, 2019·Human Vaccines & Immunotherapeutics·John J Suschak, Connie S Schmaljohn
Oct 7, 2020·Health Expectations : an International Journal of Public Participation in Health Care and Health Policy·Dong DongSamuel Yeung-Shan Wong
Nov 6, 2020·Médecine sciences : M/S·Baptiste MartinOlivier Reynard
Dec 29, 2020·Advanced Drug Delivery Reviews·Jee Young ChungYoung Jik Kwon
Jan 14, 2021·The New England Journal of Medicine·Jerald SadoffHanneke Schuitemaker
Dec 7, 2019·Journal of Autoimmunity·Manuel RojasJuan-Manuel Anaya
Feb 10, 2021·Der Internist·M AugustinS Nitschmann
Feb 14, 2021·Journal for Immunotherapy of Cancer·Maria HinterbergerJosé Medina-Echeverz
Dec 19, 2020·Nature Medicine·Jordan R BarrettUNKNOWN Oxford COVID Vaccine Trial Group
Dec 30, 2020·International Journal of Molecular Sciences·Jung-Hyun Won, Howard Lee
Jan 11, 2021·Advanced Drug Delivery Reviews·Deborah PushparajahRoderick A Slavcev
Dec 3, 2020·Canadian Journal of Microbiology·Raquel L RussellBrian L Mark
Jan 31, 2021·NPJ Vaccines·Helen R WagstaffeMartin R Goodier
Feb 25, 2021·Therapeutic Delivery·Seyed H ShahcheraghiMurtaza M Tambuwala
Mar 8, 2021·Vaccine·Jerome CustersUNKNOWN Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG)
Apr 1, 2021·Journal of Biomaterials Science. Polymer Edition·Md Mohosin Rana
Oct 21, 2020·Vaccine·Ariane VolkmannUNKNOWN Brighton Collaboration Viral Vector Vaccines Safety Working Group V3SWG
Jul 17, 2021·Human Vaccines & Immunotherapeutics·Alhassane DialloFlorence Galtier

❮ Previous
Next ❯

Datasets Mentioned

BETA
VAC52150EBL1004

Methods Mentioned

BETA
enzyme-linked immunosorbent assay
ELISA

Clinical Trials Mentioned

NCT02376400
NCT02564523
NCT02509494
NCT02325050
NCT02598388

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.